The role of the gut microbiota in NAFLD

Nature Reviews Gastroenterology and Hepatology

Volumn 13, Issue 7, 2016, Pages 412-425

  Leung, Christopher ^a,b   Rivera, Leni ^a,c   Furness, John B ^a   Angus, Peter W ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HOSPITAL   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANGIOPOIETIN; BERBERINE; BILE ACID; BINDING PROTEIN; CAFFEINE; CARBOHYDRATE RESPONSIVE ELEMENT BINDING PROTEIN; CHOLESTEROL; CHOLINE; FASTING INDUCED ADIPOCYTE FACTOR; FRUCTOSE; G PROTEIN COUPLED RECEPTOR; METHYLAMINE; OBETICHOLIC ACID; PREBIOTIC AGENT; PROBIOTIC AGENT; SHORT CHAIN FATTY ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SUCROSE; SWEETENING AGENT; UNCLASSIFIED DRUG; VSL3; GLUCOSE; PHOSPHATIDYLCHOLINE; VOLATILE FATTY ACID;

DIET; DRUG MECHANISM; DYSBIOSIS; ENTERITIS; ENVIRONMENTAL FACTOR; EXERCISE; FAT INTAKE; GASTROINTESTINAL MOTILITY DISORDER; GLUCONEOGENESIS; HEPATITIS; HUMAN; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LIFESTYLE; LIVER FIBROSIS; LIVER INJURY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBSERVATIONAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SLEEP; TEA; BIOSYNTHESIS; DISEASE COURSE; FUNGUS; GASTROINTESTINAL MOTILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOST PATHOGEN INTERACTION; INTESTINE; LIVER; METABOLISM; MICROBIOLOGY; PERMEABILITY; PHYSIOLOGY; VIRUS;

BILE ACIDS AND SALTS; DIET; DISEASE PROGRESSION; ETHANOL; EXERCISE; FATTY ACIDS, VOLATILE; FUNGI; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL MOTILITY; GLUCOSE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINES; LIVER; METHYLAMINES; NON-ALCOHOLIC FATTY LIVER DISEASE; PERMEABILITY; PHOSPHATIDYLCHOLINES; PREBIOTICS; PROBIOTICS; RECEPTORS, G-PROTEIN-COUPLED; SLEEP; VIRUSES;

EID: 84976316574     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2016.85     Document Type: Review

References (195)

1. Loomba, R., & Sanyal, A. J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 686-690 (2013
2. Farrell, G. C., & Larter, C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99-S112 (2006
3. Wong, R. J., Cheung, R., & Ahmed, A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59, 2188-2195 (2014
4. Basaranoglu, M., Basaranoglu, G., & Sentürk, H. From fatty liver to fibrosis: a tale of 'second hit'. World J. Gastroenterol. 19, 1158 (2013
5. Manti, S., et al. Nonalcoholic fatty liver disease/non alcoholic steatohepatitis in childhood: endocrine metabolic 'mal-programming'. Hepat. Mon. 14, e17641 (2014
6. Williams, C. D., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140, 124-131 (2011
7. Mouzaki, M., & Allard, J. P. The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 46, 457-467 (2012
8. Goodwin, M., et al. Advanced glycation end products augment experimental hepatic fibrosis. J. Gastroenterol. Hepatol. 28, 369-376 (2013
9. Tarantino, G., Savastano, S., & Colao, A. Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J. Gastroenterol. 16, 4773-4783 (2010
10. Compare, D., et al. Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 22, 471-476 (2012
11. Volynets, V., et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig. Dis. Sci. 57, 1932-1941 (2012
12. Backhed, F. in A Systems Biology Approach to Study Metabolic Syndrome (eds Oresic, M., & Vidal-Puig, A.) 171-181 (Springer International Publishing AG, 2014
13. Rinella, M. E., & Sanyal, A. J. NAFLD in 2014: genetics, diagnostics and therapeutic advances in NAFLD. Nat. Rev. Gastroenterol. Hepatol. 12, 65-66 (2015
14. Khalid, Q., Bailey, I., & Patel, V. Non Al coholic fatty liver disease: the effect of bile acids and farnesoid X recep-tor agonists on pathophysiology and treatment. Liver Res. Open J. 1, 32-40 (2015
15. Ursell, L. K., et al. The interpersonal and intrapersonal diversity of human-associated microbiota in key body sites. J. Allergy Clin. Immunol. 129, 1204-1208 (2012
16. The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 486, 207-214 (2012
17. Tremaroli, V., & Backhed, F. Functional interactions between the gut microbiota and host metabolism. Nature 489, 242-249 (2012
18. Reinhardt, C., Reigstad, C. S., & Bäckhed, F. Intestinal microbiota during infancy and its implications for obesity. J. Pediatr. Gastroenterol. Nutr. 48, 249-256 (2009
19. Cox, L. M., et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 158, 705-721 (2014
20. White, D. G., et al. The isolation of antibiotic-resistant Salmonella from retail ground meats. N. Engl. J. Med. 345, 1147-1154 (2001
21. Loftus, E. V., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54, 91-96 (2005
22. Wigg, A., et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut 48, 206-211 (2001
23. Turnbaugh, P. J., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1131 (2006
24. Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022-1023 (2006
25. Membrez, M., et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J. 22, 2416-2426 (2008
26. Mazagova, M., et al. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J. 29, 1043-1055 (2015
27. Cho, I., et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 488, 621-626 (2012
28. Vrieze, A., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143, 913-916.e7 (2012
29. Turnbaugh, P. J., et al. A core gut microbiome in obese and lean twins. Nature 457, 480-484 (2009
30. Siddiqui, M. S., et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin. Gastroenterol. Hepatol. 13, 1000-1008.e3 (2015
31. Stams, A. J. M., & Plugge, C. M. Electron transfer in syntrophic communities of anaerobic bacteria and archaea. Nat. Rev. Microbiol. 7, 568-577 (2009
32. Sinal, C. J., et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731-744 (2000
33. Carr, R. M., & Reid, A. E. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr. Atheroscler. Rep. 17, 1-14 (2015
34. Neuschwander-Tetri, B. A., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956-965 (2015
35. Musso, G., Cassader, M., & Gambino, R. Trials of obeticholic acid for non-alcoholic steatohepatitis. Lancet 386, 27 (2015
36. Armstrong, M. J., & Newsome, P. N. Trials of obeticholic acid for non-alcoholic steatohepatitis. Lancet 386, 28 (2015
37. Jiang, C., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest. 125, 386-402 (2015
38. Tuominen, I., & Beaven, S. W. Intestinal farnesoid X receptor puts a fresh coat of wax on fatty liver. Hepatology 62, 646-648 (2015
39. Duncan, S. H., Louis, P., Thomson, J. M., & Flint, H. J. The role of pH in determining the species composition of the human colonic microbiota. Environ. Microbiol. 11, 2112-2122 (2009
40. Arslan, N. Obesity, fatty liver disease and intestinal microbiota. World J. Gastroenterol. 20, 16452-16463 (2014
41. Hara, H., Haga, S., Aoyama, Y., & Kiriyama, S. Short-chain fatty acids suppress cholesterol synthesis in rat liver and intestine. J. Nutr. 129, 942-948 (1999
42. den Besten, G., et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation. Diabetes 64, 2398-2408 (2015
43. Brüssow, H., & Parkinson, S. J. You are what you eat. Nat. Biotechnol. 32, 243-245 (2014
44. Subramanian, S., et al. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J. Lipid Res. 52, 1626-1635 (2011
45. Wostmann, B. S., Larkin, C., Moriarty, A., & Bruckner Kardoss, E. Dietary intake, energy metabolism, and excretory losses of adult male germfree Wistar rats. Lab. Anim. Sci. 33, 46-50 (1983
46. Webb, P., & Annis, J. Adaptation to overeating in lean and overweight men and women. Hum. Nutr. Clin. Nutr. 37, 117-131 (1983
47. Jumpertz, R., et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am. J. Clin. Nutr. 94, 58-65 (2011
48. Mouzaki, M., et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58, 120-127 (2013
49. De Wit, N., et al. Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 303, G589-G599 (2012
50. Boursier, J., & Diehl, A. M. Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog. 11, e1004559 (2015
51. Alkhouri, N., et al. Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. J. Hepatol. 57, 1312-1318 (2012
52. Wong, V., et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis - a longitudinal study. PLoS ONE 8, e62885 (2013
53. Raman, M., et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 11, 868-875.e3 (2013
54. Jiang, W., et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci. Rep. 5, 8096 (2015
55. Zhu, L., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57, 601-609 (2013
56. Musso, G., Gambino, R., & Cassader, M. Obesity, diabetes, and gut microbiota the hygiene hypothesis expanded? Diabetes Care 33, 2277-2284 (2010
57. Svegliati-Baroni, G., et al. Glucagon-like peptide 1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 31, 1285-1297 (2011
58. Ulven, T. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front. Endocrinol. (Lausanne) 3, 111 (2012
59. Bollrath, J., & Powrie, F. Feed your Tregs more fiber. Science 341, 463-464 (2013
60. Furusawa, Y., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446-450 (2013
61. Delaere, F., et al. The role of sodium-coupled glucose co transporter 3 in the satiety effect of portal glucose sensing. Mol. Metab. 2, 47-53 (2013
62. Troy, S., et al. Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab. 8, 201-211 (2008
63. Bäckhed, F., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl Acad. Sci. USA 101, 15718-15723 (2004
64. Alex, S., et al. Short-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor γ. Mol. Cell Biol. 33, 1303-1316 (2013
65. Trinchese, G., et al. Human, donkey and cow milk differently affects energy efficiency and inflammatory state by modulating mitochondrial function and gut microbiota. J. Nutr. Biochem. 26, 1136-1146 (2015
66. Cani, P. D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761-1772 (2007
67. Mao, J. W., et al. Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease. Int. J. Clin. Exp. Pathol. 8, 3648-3658 (2015
68. Kohjima, M., et al. SREBP 1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int. J. Mol. Med. 21, 507-511 (2008
69. Hur, W., et al. Downregulation of microRNA 451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway. Int. J. Biochem. Cell Biol. 64, 265-276 (2015
70. Zhang, M., et al. Enhanced AMPK phosphorylation contributes to the beneficial effects of Lactobacillus rhamnosus GG supernatant on chronic-alcohol-induced fatty liver disease. J. Nutr. Biochem. 26, 337-344 (2015
71. Than, N. N., & Newsome, P. N. A concise review of non alcoholic fatty liver disease. Atherosclerosis 239, 192-202 (2015
72. Mencin, A., Kluwe, J., & Schwabe, R. F. Toll-like receptors as targets in chronic liver diseases. Gut 58, 704-720 (2009
73. Federico, A., Dallio, M., Godos, J., Loguercio, C., & Salomone, F. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl. Res. 167, 116-124 (2016
74. Friedman, S. L. A deer in the headlights: BAMBI meets liver fibrosis. Nat. Med. 13, 1281-1282 (2007
75. Takaki, A., Kawai, D., & Yamamoto, K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int 15, 7352-7379 (2014
76. Tyrer, P. C., Bean, E. G., Ruth Foxwell, A., & Pavli, P. Effects of bacterial products on enterocyte-macrophage interactions in vitro. Biochem. Biophys. Res. Commun. 413, 336-341 (2011
77. Baldwin, A. S. Jr. The NF κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol. 14, 649-681 (1996
78. Everard, A., et al. Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status. Nat. Commun. 5, 5648 (2014
79. Dixon, L. J., Flask, C. A., Papouchado, B. G., Feldstein, A. E., & Nagy, L. E. Caspase 1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis. PLoS ONE 8, e56100 (2013
80. Friedman, S. L. Liver fibrosis in 2012: convergent pathways that cause hepatic fibrosis in NASH. Nat. Rev. Gastroenterol. Hepatol. 10, 71-72 (2013
81. Wree, A., et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J. Mol. Med. 92, 1069-1082 (2014
82. Henao-Mejia, J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179-185 (2012
83. Vijay-Kumar, M., & Gewirtz, Andrew, T. Is predisposition to NAFLD and obesity communicable? Cell Metab. 15, 419-420 (2012
84. Wang, L., et al. Methods to determine intestinal permeability and bacterial translocation during liver disease. J. Immunol. Methods 421, 44-53 (2015
85. Miki, K., Butler, R., Moore, D., & Davidson, G. Rapid and simultaneous quantification of rhamnose, mannitol, and lactulose in urine by HPLC for estimating intestinal permeability in pediatric practice. Clin. Chem. 42, 71-75 (1996
86. van Wijck, K., et al. Novel multi-sugar assay for site specific gastrointestinal permeability analysis: a randomized controlled crossover trial. Clin. Nutr. 32, 245-251 (2013
87. Miele, L., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49, 1877-1887 (2009
88. Arasaradnam, R. P., et al. Evaluation of gut bacterial populations using an electronic e nose and field asymmetric ion mobility spectrometry: further insights into 'fermentonomics'. J. Med. Eng. Technol. 36, 333-337 (2012
89. Verdam, F. J., Rensen, S. S., Driessen, A., Greve, J. W., & Buurman, W. A. Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 45, 149-152 (2011
90. Tarantino, G., Scalera, A., & Finelli, C. Liver-spleen axis: intersection between immunity, infections and metabolism. World J. Gastroenterol. 19, 3534-3542 (2013
91. Duman, D. G., et al. Colloid scintigraphy in non-alcoholic steatohepatitis: a conventional diagnostic method for an emerging disease. Nucl. Med. Commun. 27, 387-393 (2006
92. Rosser, E. C., et al. Regulatory B cells are induced by gut microbiota-driven interleukin 1β and interleukin 6 production. Nat. Med. 20, 1334-1339 (2014
93. Yuan, J., et al. Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 29, 1292-1298 (2014
94. Thuy, S., et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J. Nutr. 138, 1452-1455 (2008
95. Guerra Ruiz, A., et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes. Surg. 17, 1374-1380 (2007
96. Rivera, L. R., et al. Damage to enteric neurons occurs in mice that develop fatty liver disease but not diabetes in response to a high-fat diet. Neurogastroenterol. Motil. 26, 1188-1199 (2014
97. Jalanka-Tuovinen, J., et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 63, 1737-1745 (2014
98. Dawes, E., & Foster, S. M. The formation of ethanol in Escherichia coli. Biochim. Biophys. Acta 22, 253-265 (1956
99. Cope, K., Risby, T., & Diehl, A. M. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 119, 1340-1347 (2000
100. Nair, S., Cope, K., Terence, R. H., & Diehl, A. M. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am. J. Gastroenterol. 96, 1200-1204 (2001
101. Baker, S. S., Baker, R. D., Liu, W., Nowak, N. J., & Zhu, L. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS ONE 5, e9570 (2010
102. Parlesak, A., Schäfer, C., Schütz, T., Bode, J. C., & Bode, C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J. Hepatol. 32, 742-747 (2000
103. Wang, Z., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57-63 (2011
104. Spencer, M. D., et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 140, 976-986 (2011
105. Dumas, M. E., et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc. Natl Acad. Sci. USA 103, 12511-12516 (2006
106. Savard, C., et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology 57, 81-92 (2013
107. de Wit, N., et al. Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. Am. J. Gastrointest. Liver Physiol. 303, G589-G599 (2012
108. Caesar, R., Tremaroli, V., Kovatcheva-Datchary, P., Cani, Patrice, D., & Bäckhed, F. Crosstalk between gut microbiota and dietary lipids aggravates WAT Inflammation through TLR signaling. Cell Metab. 22, 658-668 (2015
109. Jakobsdottir, G., Xu, J., Molin, G., Ahrne, S., & Nyman, M. High-fat diet reduces the formation of butyrate, but increases succinate, inflammation, liver fat and cholesterol in rats, while dietary fibre counteracts these effects. PLoS ONE 8, e80476 (2013
110. Jin, C. J., Sellmann, C., Engstler, A. J., Ziegenhardt, D., & Bergheim, I. Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH). Br. J. Nutr. 114, 1745-1755 (2015
111. Wagnerberger, S., et al. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br. J. Nutr. 107, 1727-1738 (2012
112. Ishimoto, T., et al. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology 58, 1632-1643 (2013
113. Donnelly, K. L., et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115, 1343-1351 (2005
114. Lambert, J. E., Ramos-Roman, M. A., Browning, J. D., & Parks, E. J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146, 726-735 (2014
115. Stanhope, K. L., et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J. Clin. Invest. 119, 1322-1334 (2009
116. Timlin, M. T., & Parks, E. J. Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. Am. J. Clin. Nutr. 81, 35-42 (2005
117. Softic, S., Cohen, D. E., & Kahn, C. R. Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Dig. Dis. Sci. 61, 1282-1293 (2016
118. Ma, J., et al. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. J. Hepatol. 63, 462-469 (2015
119. Chiavaroli, L., Ha, V., de Souza, R. J., Kendall, C. W., & Sievenpiper, J. L. Overstated associations between fructose and nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 60, e35 (2015
120. Abdelmalek, M. F., & Day, C. Sugar sweetened beverages and fatty liver disease: rising concern and call to action. J. Hepatol. 63, 306-308 (2015
121. Yap, Y. T., et al. Advanced glycation end products as environmental risk factors for the development of type 1 diabetes. Curr. Drug Targets 13, 526-540 (2012
122. Rojas, A., et al. Evidence of involvement of the receptor for advanced glycation end-products (RAGE) in the adhesion of Helicobacter pylori to gastric epithelial cells. Microbes Infect. 13, 818-823 (2011
123. Däbritz, J., et al. The functional -374T/A polymorphism of the receptor for advanced glycation end products may modulate Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G823-G832 (2011
124. Ciccocioppo, R., et al. Role of the advanced glycation end products receptor in Crohn's disease inflammation. World J. Gastroenterol. 19, 8269-8281 (2013
125. Leung, C., et al. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J. Hepatol. 60, 832-838 (2014
126. Suez, J., et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 514, 181-186 (2014
127. Payne, A. N., Chassard, C., & Lacroix, C. Gut microbial adaptation to dietary consumption of fructose, artificial sweeteners and sugar alcohols: implications for host-microbe interactions contributing to obesity. Obes. Rev. 13, 799-809 (2012
128. Swithers, S. E. Artificial sweeteners produce the counterintuitive effect of inducing metabolic derangements. Trends Endocrinol. Metab. 24, 431-441 (2013
129. AlKhater, S. A. Paediatric non-alcoholic fatty liver disease: an overview. Obes. Rev. 16, 393-405 (2015
130. Bergheim, I., et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J. Hepatol. 48, 983-992 (2008
131. Trocho, C., et al. Formaldehyde derived from dietary aspartame binds to tissue components in vivo. Life Sci. 63, 337-349 (1998
132. Imaizumi, K., Nakatsu, Y., Sato, M., Sedarnawati, Y., & Sugano, M. Effects of xylooligosaccharides on blood glucose, serum and liver lipids and cecum short-chain fatty acids in diabetic rats. Agric. Biol. Chem. 55, 199-205 (1991
133. Hashemi Kani, A., Alavian, S. M., Haghighatdoost, F., & Azadbakht, L. Diet macronutrients composition in nonalcoholic fatty liver disease: a review on the related documents. Hepat. Mon. 14, e10939 (2014
134. Seo, D. B., et al. Fermented green tea extract alleviates obesity and related complications and alters gut microbiota composition in diet-induced obese mice. J. Med. Food 18, 549-556 (2015
135. Zhou, J., et al. Epigallocatechin 3 gallate (EGCG), a green tea polyphenol, stimulates hepatic autophagy and lipid clearance. PLoS ONE 9, e87161 (2014
136. Santamarina, A. B., et al. Decaffeinated green tea extract rich in epigallocatechin 3 gallate prevents fatty liver disease by increased activities of mitochondrial respiratory chain complexes in diet-induced obesity mice. J. Nutr. Biochem. 26, 1348-1356 (2015
137. Imatoh, T., Kamimura, S., & Miyazaki, M. Coffee but not green tea consumption is associated with prevalence and severity of hepatic steatosis: the impact on leptin level. Eur. J. Clin. Nutr. 69, 1023-1027 (2015
138. Pezeshki, A., Safi, S., Feizi, A., Askari, G., & Karami, F. The effect of green tea extract supplementation on liver enzymes in patients with nonalcoholic fatty liver disease. Int. J. Prev. Med. 6, 131 (2015
139. Molloy, J. W., et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 55, 429-436 (2012
140. Vitaglione, P., et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology 52, 1652-1661 (2010
141. Shen, L. Letter: gut microbiota modulation contributes to coffee's benefits for non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 39, 1441-1442 (2014
142. Nakayama, T., & Oishi, K. Influence of coffee (Coffea arabica) and galacto-oligosaccharide consumption on intestinal microbiota and the host responses. FEMS Microbiol. Lett. 343, 161-168 (2013
143. Cowan, T. E., et al. Chronic coffee consumption in the diet-induced obese rat: impact on gut microbiota and serum metabolomics. J. Nutr. Biochem. 25, 489-495 (2014
144. Dong, H., Lu, F. e., & Zhao, L. Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease. Chin. J. Integr. Med. 18, 152-160 (2012
145. Yin, X., et al. Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula. Syst. Appl. Microbiol. 36, 188-196 (2013
146. Yi, C., Leiming, X., & Qin, P. Modulation of gut microbiota with berberine improves nonalcoholic steatohepatitis in mice. J. Clin. Hepatol. 2, 015 (2013
147. Spiegel, K., Tasali, E., Leproult, R., & Van Cauter, E. Effects of poor and short sleep on glucose metabolism and obesity risk. Nat. Rev. Endocrinol. 5, 253-261 (2009
148. Nedeltcheva, A. V., Kilkus, J. M., Imperial, J., Schoeller, D. A., & Penev, P. D. Insufficient sleep undermines dietary efforts to reduce adiposity. Ann. Intern. Med. 153, 435-441 (2010
149. Voigt, R. M., et al. Circadian disorganization alters intestinal microbiota. PLoS ONE 9, e97500 (2014
150. Summa, K. C., et al. Disruption of the circadian clock in mice increases intestinal permeability and promotes alcohol-induced hepatic pathology and inflammation. PLoS ONE 8, e67102 (2013
151. Dvornyk, V., Vinogradova, O., & Nevo, E. Origin and evolution of circadian clock genes in prokaryotes. Proc. Natl Acad. Sci. USA 100, 2495-2500 (2003
152. Musso, G., et al. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta analysis. Obes. Rev. 14, 417-431 (2013
153. Mishra, P., et al. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int. 28, 1080-1086 (2008
154. Zamora-Valdés, D., & Méndez-Sánchez, N. Experimental evidence of obstructive sleep apnea syndrome as a second hit accomplice in nonalcoholic steatohepatitis pathogenesis. Ann. Hepatol. 6, 281-283 (2007
155. Moreno-Indias, I., et al. Intermittent hypoxia alters gut microbiota diversity in a mouse model of sleep apnoea. Eur. Respir. J. 45, 1055-1065 (2015
156. Finelli, C., & Tarantino, G. Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients. J. Gastrointest. Liver Dis. 21, 293-302 (2012
157. Targher, G., & Arcaro, G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 191, 235-240 (2007
158. Conn, V. S., Hafdahl, A. R., Cooper, P. S., Brown, L. M., & Lusk, S. L. Meta-analysis of workplace physical activity interventions. Am. J. Prev. Med. 37, 330-339 (2009
159. Evans, C. C., et al. Exercise prevents weight gain and alters the gut microbiota in a mouse model of high fat diet-induced obesity. PLoS ONE 9, e92193 (2014
160. Matsumoto, M., et al. Voluntary running exercise alters microbiota composition and increases n butyrate concentration in the rat cecum. Biosci. Biotechnol. Biochem. 72, 572-576 (2008
161. Clarke, S. F., et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut 63, 1913-1920 (2014
162. Everard, A., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet induced obesity. Proc. Natl Acad. Sci. USA 110, 9066-9071 (2013
163. Murase, T., Haramizu, S., Shimotoyodome, A., Tokimitsu, I., & Hase, T. Green tea extract improves running endurance in mice by stimulating lipid utilization during exercise. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R1550-R1556 (2006
164. Patel, R., & DuPont, H. L. New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. Clin. Infect. Dis. 60, S108-S121 (2015
165. Ferolla, S. M., Armiliato, G. N. d. A., Couto, C. A., & Ferrari, T. C. A. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J. Hepatol. 7, 559-565 (2015
166. Alisi, A., et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 39, 1276-1285 (2014
167. Lee, J., Hong, S. W., Rhee, E. J., & Lee, W. Y. GLP 1 receptor agonist and non-alcoholic fatty liver disease. Diabetes Metab. J. 36, 262-267 (2012
168. Campbell, J. E., & Drucker, D. J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17, 819-837 (2013
169. Malaguarnera, M., et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig. Dis. Sci. 57, 545-553 (2012
170. Wong, V., et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof of concept study. Ann. Hepatol. 12, 256-262 (2013
171. Beserra, B. T., et al. A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity. Clin. Nutr. 34, 845-858 (2015
172. Beserra, B. T. S., et al. A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity. Clin. Nutr. 34, 845-858 (2015
173. Tarantino, G., & Finelli, C. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol. 10, 889-902 (2015
174. Miloh, T. Probiotics in pediatric liver disease. J. Clin. Gastroenterol. 49, S33-S36 (2015
175. Anand, G., Zarrinpar, A., & Loomba, R. in Seminars in Liver Disease 37-47 (Thieme Medical Publishers, 2016
176. Frei, R., Akdis, M., & O'Mahony, L. Prebiotics, probiotics, synbiotics, and the immune system: experimental data and clinical evidence. Curr. Opin. Gastroenterol. 31, 153-158 (2015
177. Younossi, Z., Reyes, M., Mishra, A., Mehta, R., & Henry, L. Systematic review with meta-analysis: non alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment. Pharmacol. Ther. 39, 3-14 (2014
178. Mudaliar, S., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574-582.e1 (2013
179. Safadi, R., et al. The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 12, 2085-2091.e1 (2014
180. Marra, F., & Tacke, F. Roles for chemokines in liver disease. Gastroenterology 147, 577-594. e571 (2014
181. Ratziu, V. Pharmacological agents for NASH. Nat. Rev. Gastroenterol. Hepatol. 10, 676-685 (2013
182. Gastaldelli, A., & Marchesini, G. Time for Glucagon like peptide 1 receptor agonists treatment for patients with NAFLD? J. Hepatol. 64, 262-264 (2016
183. Staels, B., et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 58, 1941-1952 (2013
184. Cho, I., & Blaser, M. J. The human microbiome: at the interface of health and disease. Nat. Rev. Genet. 13, 260-270 (2012
185. Eckburg, P. B., et al. Diversity of the human intestinal microbial flora. Science 308, 1635-1638 (2005
186. Mutlu, E., et al. Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol. Clin. Exp. Res. 33, 1836-1846 (2009
187. DuPont, A. W., & DuPont, H. L. The intestinal microbiota and chronic disorders of the gut. Nat. Rev. Gastroenterol. Hepatol. 8, 523-531 (2011
188. Reyes, A., et al. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature 466, 334-338 (2010
189. Norman, J. M., Handley, S. A., & Virgin, H. W. Kingdom-agnostic metagenomics and the importance of complete characterization of enteric microbial communities. Gastroenterology 146, 1459-1469 (2014
190. Fernández, L., et al. The human milk microbiota: origin and potential roles in health and disease. Pharmacol. Res. 69, 1-10 (2013
191. De Filippo, C., et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl Acad. Sci. USA 107, 14691-14696 (2010
192. Grzeskowiak, L., et al. Distinct gut microbiota in southeastern African and northern European infants. J. Pediatr. Gastroenterol. Nutr. 54, 812-816 (2012
193. Sinkiewicz, G., & Nordstrom, E. A. 353 occurrence of Lactobacillus Reuteri, Lactobacilli and Bifidobacteria in human breast milk. Pediatr. Res. 58, 415-415 (2005
194. Nobili, V., et al. A protective effect of breastfeeding on the progression of non-alcoholic fatty liver disease. Arch. Dis. Child. 94, 801-805 (2009
195. Oben, J. A., et al. Maternal obesity during pregnancy and lactation programs the development of offspring non-alcoholic fatty liver disease in mice. J. Hepatol. 52, 913-920 (2010